The clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease | Alzheimer's Research & Therapy | Full Text

The clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease | Alzheimer's Research & Therapy | Full Text

The clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease

Synapse damage and loss are fundamental to the pathophysiology of Alzheimer’s disease (AD) and lead to reduced cognitive function. The goal of this review is to address the challenges of forging new clinical d...

Authors:Martí Colom-Cadena, Tara Spires-Jones, Henrik Zetterberg, Kaj Blennow, Anthony Caggiano, Steven T. DeKosky, Howard Fillit, John E. Harrison, Lon S. Schneider, Phillip Scheltens, Willem de Haan, Michael Grundman, Christopher H. van Dyck, Nicholas J. Izzo and Susan M. Catalano

Citation:Alzheimer's Research & Therapy 2020 12:21

Content type:Review

Published on: 2 March 2020

• ViewFull Text
 
• ViewPDF